Clinical applications - Graft engineering - Stem cell enrichment - Background

Background

CliniMACS® CD34+ or CD133+ cell enrichment with the CliniMACS System results in an enriched stem cell product which is depleted of non-target cells. The purity of CD34 enriched stem cell product is often higher than 95% and the passive T cell depletion results in a log10 depletion of about 4.5. Results after CliniMACS CD133 enrichment (healthy donors) are comparable.

Customer login

Go

Forgot password?
Register for account

0 Shopping cart

Contact

Miltenyi Biotec Inc.
Phone: +1 800 FOR MACS
Fax:+1 877 591 1060
macs@miltenyibiotec.com
Contact overview

Product finder

Antibody panel builder

Toolbox

Loading...
References

References

Change country

Please select your country to continue